No Data
No Data
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
16 New GLP-1 Weight-loss Drugs Could Be Launched by 2029: Report
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86
Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
No Data
No Data